Skip to search formSkip to main contentSkip to account menu

proxibarbal

Known as: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-, proxybarbital 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (3)

AxeenIpronalVasalgin

Broader (2)

BarbituratesHypnotics and Sedatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
[Thrombopenic purpura caused by proxibarbal].
1992
1992
[Peripheral thrombopenia secondary to proxibarbal therapy].
1989
1989
[A controlled trial of prevention of recurrence of gastroduodenal ulcers with proxybarbital].
During 3 years, the usefulness of proxibarbal (Ipronal "Polfa") for gastro-duodenal ulcer recurrences prophylaxis has been studie… 
1988
1988
[Kinetics of the changes in the proxybarbital level after its oral and intravenous administration in a monocompartmental model in humans].
1988
1988
Proxibarbal: métabolisme, distribution intracérébrale et effet sur le turn over de la 5HT dans diverses structures chez le rat
1984
1984
[Spectrophotometric and spectrofluorometric study of barbituric acid and thiobarbituric acid derivatives. I. General spectrophotometric and spectrofluorometric properties of barbituric acid…
1984
1984
[Development of proxibarbal blood levels. The role of various elimination processes].
Half-lives of barbiturates are short when their lipid solubility is high but long when they are less lipophilic. Infection of… 
1980
1980
Metabolic investigations of proxibarbal [5-allyl-5-(2-hydroxypropyl)barbituric acid] in vitro.